1-11 of 11
Scott Gettinger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Open Access
Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, Edgar Gonzalez-Kozlova, Mary W. Redman, Hong Chen, Ganiraju C. Manyam, Gayatri Kumar, Jianhua Zhang, Xingzhi Song, Rossana Lazcano, Mario L. Marques-Piubelli, Caddie Laberiano-Fernandez, Frank Rojas, Baili Zhang, Len Taing, Aashna Jhaveri, Jacob Geisberg, Jennifer Altreuter, Franziska Michor, James Provencher, Joyce Yu, Ethan Cerami, Radim Moravec, Kasthuri Kannan, Rajyalakshmi Luthra, Gheath Alatrash, Hsin-Hui Huang, Hui Xie, Manishkumar Patel, Kai Nie, Jocelyn Harris, Kimberly Argueta, James Lindsay, Roshni Biswas, Stephen Van Nostrand, Seunghee Kim-Schulze, Jhanelle E. Gray, Roy S. Herbst, Ignacio I. Wistuba, Scott Gettinger, Karen Kelly, Lyudmila Bazhenova, Sacha Gnjatic, J. Jack Lee, Jianjun Zhang, Cara Haymaker
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1655–1668.
https://doi.org/10.1158/1078-0432.CCR-23-0251
Published: 15 April 2024
View articletitled, Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Open the PDF for Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Available to Purchase
Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4757–4767.
https://doi.org/10.1158/1078-0432.CCR-21-0903
Published: 01 September 2021
View articletitled, A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Open the PDF for A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

Available to Purchase
Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4360–4368.
https://doi.org/10.1158/1078-0432.CCR-20-0175
Published: 14 August 2020
View articletitled, Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Open the PDF for Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling in another window
Includes: Supplementary data
Journal Articles

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Free
Anna Truini, Jacqueline H. Starrett, Tyler Stewart, Kumar Ashtekar, Zenta Walther, Anna Wurtz, David Lu, Jin H. Park, Michelle DeVeaux, Xiaoling Song, Scott Gettinger, Daniel Zelterman, Mark A. Lemmon, Sarah B. Goldberg, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6382–6391.
https://doi.org/10.1158/1078-0432.CCR-19-0780
Published: 01 November 2019
View articletitled, The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Open the PDF for The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Free
Ila Datar, Miguel F. Sanmamed, Jun Wang, Brian S. Henick, Jungmin Choi, Ti Badri, Weilai Dong, Nikita Mani, Maria Toki, Luis D. Mejías, Maria D. Lozano, Jose Luis Perez-Gracia, Vamsidhar Velcheti, Matthew D. Hellmann, Justin F. Gainor, Kristen McEachern, David Jenkins, Konstantinos Syrigos, Katerina Politi, Scott Gettinger, David L. Rimm, Roy S. Herbst, Ignacio Melero, Lieping Chen, Kurt A. Schalper
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4663–4673.
https://doi.org/10.1158/1078-0432.CCR-18-4142
Published: 01 August 2019
View articletitled, Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Open the PDF for Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis in another window
Includes: Supplementary data
Journal Articles

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Free
Scott Gettinger, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4539–4541.
https://doi.org/10.1158/1078-0432.CCR-16-1401
Published: 15 September 2016
View articletitled, PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Open the PDF for PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? in another window
Journal Articles

Immune Checkpoint Modulation for Non–Small Cell Lung Cancer

Free
Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, Scott Gettinger
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2256–2262.
https://doi.org/10.1158/1078-0432.CCR-14-2959
Published: 14 May 2015
View articletitled, Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
Open the PDF for Immune Checkpoint Modulation for Non–Small Cell Lung Cancer in another window
Journal Articles

Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer

Free
Katerina Politi, Scott Gettinger
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5576–5578.
https://doi.org/10.1158/1078-0432.CCR-14-2306
Published: 13 November 2014
View articletitled, Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer
Open the PDF for Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer in another window
Journal Articles

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Free
Antonio Jimeno, Glen J. Weiss, Wilson H. Miller, Jr, Scott Gettinger, Bernard J.C. Eigl, Anne Lynne S. Chang, Joi Dunbar, Shannon Devens, Kerrie Faia, Georgios Skliris, Jeff Kutok, Karl D. Lewis, Raoul Tibes, William H. Sharfman, Robert W. Ross, Charles M. Rudin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (10): 2766–2774.
https://doi.org/10.1158/1078-0432.CCR-12-3654
Published: 12 May 2013
View articletitled, Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
Open the PDF for Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors in another window
Journal Articles

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

Free
William P. Tew, Michael Gordon, John Murren, Jakob Dupont, Sandra Pezzulli, Carol Aghajanian, Paul Sabbatini, David Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 358–366.
https://doi.org/10.1158/1078-0432.CCR-09-2103
Published: 04 January 2010
View articletitled, Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
Open the PDF for Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors in another window
Journal Articles

High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

Free
Valsamo K. Anagnostou, Gerold Bepler, Konstantinos N. Syrigos, Lynn Tanoue, Scott Gettinger, Robert J. Homer, Daniel Boffa, Frank Detterbeck, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4157–4164.
https://doi.org/10.1158/1078-0432.CCR-09-0099
Published: 15 June 2009
View articletitled, High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Open the PDF for High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma in another window
Includes: Supplementary data